CAMBRIDGE, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its first quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Thursday, May 1 at 8:30 a.m., Eastern Time, to provide a summary of first quarter 2014 financial results as well as discuss the positive top line results of the combination arm of MM-398's Phase 3 NAPOLI-1 study in post-gemcitabine metastatic pancreatic cancer announced this morning.
Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 37032608. A listen-only webcast of the call can be accessed in the Investors section of Merrimack's website, http://investors.merrimackpharma.com, and a replay of the call will be archived there for six weeks following the call.
Key Recent Events
- Merrimack announced in a separate release this morning that in a Phase 3 study in patients with metastatic pancreatic cancer, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin. The NAPOLI-1 study was completed in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. The primary log-rank analysis of overall survival was statistically significant (p=0.012) with a corresponding hazard ratio of 0.67. A statistically significant advantage for progression free survival was also observed in the combination arm. The most common Grade 3 or higher adverse events in the combination arm were neutropenia, fatigue, diarrhea and vomiting. The arm evaluating MM-398 as a monotherapy did not meet the statistical endpoint. The hazard ratio for overall survival in the monotherapy arm was 0.99 with a corresponding p-value of 0.942. The study has been accepted for oral presentation at the European Society for Medical Oncology (ESMO) World Conference on Gastrointestinal Cancer being held in Barcelona, Spain on June 25-28, 2014.
- Merrimack also recently announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol*, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment. Data from the first cohort of patients in this study, which was completed in conjunction with the Virginia G. Piper Cancer Center and Imaging Endpoints, were presented at the American Association of Cancer Research Annual Meeting, April 5-9, 2014, in San Diego, California.
Merrimack anticipates the following upcoming milestones:
- Presentation of MM-121 Phase 2 data at the 2014 Annual Meeting of the American Society of Clinical Oncology in Chicago;
- Presentation of MM-398 Phase 3 NAPOLI-1 results at the ESMO World Congress on Gastrointestinal Cancer 2014 in Barcelona;
- Announcement of top line data for the Phase 2 triple negative breast cancer cohort of MM-121 in the neoadjuvant setting in the second quarter of 2014;
- Continued enrollment in the Phase 2 program for MM-111 in gastric, esophageal and gastroesophageal cancers;
- Initiation of a Phase 2 clinical study for MM-302 in 2014;
- Initiation of a Phase 2 clinical study for MM-151 in 2014; and
- Initiation of a Phase 2 clinical study for MM-141 in 2014.
Merrimack expects to attend a number of investor conferences in the months ahead, including:
- Bank of America Merrill Lynch 2014 Health Care Conference, May 14 in Las Vegas; and
- UBS 2014 Global Healthcare Conference, May 19-21 in New York City.
First Quarter 2014 Financial Results
Net loss for the first quarter of 2014 was $27.8 million, or basic and diluted net loss per share available to common stockholders of $0.27, compared with net loss for the first quarter of 2013 of $28.3 million, or basic and diluted net loss per share available to common stockholders of $0.29. This decrease in net loss was primarily attributable to four factors:
- A $9.0 million non-recurring decrease in net loss related to the MM-121 program – $5.8 million of this decrease relates to an increase in revenue in the first quarter of 2014 due to Merrimack receiving budget approval from Sanofi during the quarter for the funding of expenses recognized in 2013, and $3.2 million of this decrease relates to a reduction in MM-121 expenses during the first quarter of 2014 due to a credit received from an agreement with a contract research organization;
- $3.8 million of increased research and development expense not associated with MM-121, which was primarily due to increased spending on Merrimack's other clinical stage product candidates;
- $3.3 million of increased interest expense from Merrimack's 4.50% convertible senior notes, which were issued in July 2013, of which $1.9 million is imputed non-cash expense primarily related to the conversion feature of the convertible senior notes; and
- $1.3 million of increased general and administrative expense primarily associated with increased headcount costs to support clinical development, increased rent expense and increased costs to support preliminary commercialization efforts on MM-398.
Merrimack expects its existing unrestricted cash and cash equivalents and available-for-sale securities as of March 31, 2014 of $124.2 million, anticipated interest income and reimbursement of expenses under its license and collaboration agreement with Sanofi related to MM-121 to be sufficient to fund operations and pre-commercial efforts into 2015.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack currently has six oncology therapeutics in clinical development and three additional candidates in late stage preclinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com.
Cautionary Note on Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack's strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. In this press release, Merrimack's forward-looking statements include statements about the potential effectiveness and safety profile of MM-398 either alone or in combination, the potential to develop ferumoxytol as a predictive diagnostic, the potential to identify patients most likely to benefit from MM-398, the timing of availability of clinical trial data, Merrimack's ability to translate clinical data into future clinical success, anticipated milestones, including the initiation of new trials, Merrimack's presentations at upcoming investor and scientific conferences and expectations regarding the sufficiency of Merrimack's financial resources to fund operations. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, development progress of Merrimack's companion diagnostics, availability of funding sufficient for Merrimack's foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other matters that could affect the availability or commercial potential of Merrimack's drug candidates or companion diagnostics. Merrimack undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing Merrimack's views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Merrimack's business in general, see the "Risk Factors" section of Merrimack's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 4, 2014 and other reports Merrimack files with the SEC.
|*Ferumoxytol, commercially available as Feraheme® (AMAG Pharmaceuticals), is an iron-oxide, super-paramagnetic nanoparticle, known to be taken up by macrophages and for exhibiting magnetic resonance imaging properties. The U.S. Food and Drug Administration has approved ferumoxytol for intravenous use as an iron replacement product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). The use of ferumoxytol in the pilot study mentioned above is for clinical investigational studies only|
|Merrimack Pharmaceuticals, Inc.|
|Unaudited Condensed Consolidated Statements of Comprehensive Loss|
|(in thousands, except per share amounts)|
|Three Months Ended March 31|
|Collaboration revenues||$ 13,034||$ 14,655|
|Research and development||30,324||36,989|
|General and administrative||6,224||4,932|
|Total operating expenses||36,548||41,921|
|Loss from operations||(23,514)||(27,266)|
|Other income and expenses, net||(4,240)||(1,057)|
|Less net loss attributable to non-controlling interest||(169)||(170)|
|Net loss attributable to Merrimack||$ (27,585)||$ (28,153)|
|Other comprehensive income||16||18|
|Net loss per share available to stockholders - basic and diluted||($0.27)||($0.29)|
|Weighted-average common shares used in computing net loss per share available to common stockholders - basic and diluted||102,888||95,879|
|Merrimack Pharmaceuticals, Inc.|
|Unaudited Balance Sheet Data|
| As of |
March 31, 2014
| As of |
December 31, 2013
|Cash, cash equivalents and available-for-sale securities||$124,176||$155,202|
|Total stockholders' deficit||(65,964)||(43,465)|
|Merrimack Pharmaceuticals, Inc.|
|Unaudited Cash Flow Data|
|Three Months Ended March 31,|
|Net cash used in operating activities||($31,387)||($21,196)|
|Net cash provided by investing activities||31,064||11,506|
|Net cash provided by financing activities||2,134||411|
|Net increase (decrease) in cash and cash equivalents||1,811||(9,279)|
CONTACT: Investor Contact: Geoffrey M. Grande, CFA Investor Relations Merrimack 617-441-7602 firstname.lastname@example.org Media Contact: Dana Robie Corporate Communications Merrimack 617-441-7408 email@example.com